Asprin and statin use for management of atherosclerotic cardiovascular disease in liver transplant candidates: Are we missing the mark?

Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association

“…144,145 Statins are underused in patients with liver disease, 146–148 including those patients with confirmed angiographic CAD. 98,149 Statin use in patients with advanced liver disease, including compensated cirrhosis, appears to be safe and beneficial, although the risk of muscle-related side effects is higher and may be additive to risk conferred by other factors. 150 In liver transplantation candidates with Child-Turcotte-Pugh (CTP) class A or B cirrhosis and clinical CAD, evidence favors statin use for secondary prevention with close monitoring of liver chemistries and markers of rhabdomyolysis.…”

Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury

“…Recent studies confirmed that simvastatin decreases portal pressure [ 75 ]. Statins decrease hepatic fibrogenesis, protect from severe LC complications and even reduce the risk of hepatocellular carcinoma by improving inflammation and endothelial dysfunction [ 76 ]. It has to be mentioned that data on the use of statins in patients with decompensated LC are very limited.…”

Crossing the Boundaries of Treatment of Valvular Heart Disease in Patients With Liver Cirrhosis

“…Whereas mild to moderate valvular heart diseases are usually well tolerated during the surgical procedure, severe valvular heart diseases preclude liver transplant in most of centres. Severe or symptomatic AS, if nor corrected, precludes the LT, due to severe hemodynamic instability, critically reduced myocardial perfusion, and poor postoperative outcome (22). Cardiovascular complications are the most important cause of early death and one of the most frequent causes of long-term death after LT (23).…”